30 results on '"Fröhling S"'
Search Results
2. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
3. Optimizing panel-based tumor mutational burden (TMB) measurement
4. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
5. 56P Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
6. 210P Therapeutic implications of phosphoproteomics in molecular cancer diagnostics
7. 198P Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
8. 196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
9. 1784TiP Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study
10. 1772P Phosphoproteomic biomarker for afatinib response stratification in advanced chordoma
11. 2318P Value of broad molecular profiling for cancer diagnosis
12. 2320P Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
13. 1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
14. 1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
15. 187P Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
16. 131O A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort
17. 1490MO CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
18. 668P Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC)
19. 487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
20. 1533P Gene expression-based prediction of pazopanib benefit in sarcomas
21. 120TiP - EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe
22. 97P - Community-driven development of a modified progression-free survival ratio for precision oncology trials
23. 81P - Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium
24. 70P - Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures
25. 18P - Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial
26. 1979TiP - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies
27. 27P - Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
28. 1310PD - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
29. PO-451 Targeted proteomics to improve therapy stratification of cancer patients
30. 1526TiP - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.